| HOME >> MEDICINE >> TECHNOLOGY |
60,66666,61263,30666,216Weighted average unvested restricted stock awards (1)
75324111387Shares used in calculation of diluted net income from continuing operations per share -- non-GAAP
60,74166,93663,41766,603(1) The company adopted the two-class method in calculating net income per share on a GAAP basis, which excludes the weighted average unvested restricted stock awards outstanding of 75,090 and 323,582 for the three months ended October 1, 2011 and October 2, 2010, respectively, and 110,521 and 386,808 for the nine months ended October 1, 2011 and October 2, 2010, respectively. The following table reconciles the specific items excluded from GAAP gross profit and gross margin from continuing operations in the calculation of non-GAAP gross profit and gross margin from continuing operations for the periods shown below:THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Gross Profit from Continuing Operations(Unaudited)(in thousands) Three Months Ended Nine Months Ended October 1, 2011October 2, 2010October 1, 2011October 2, 2010Gross profit from continuing operations on a GAAP basis$
71,686
69.9%
$
2,375
68.5%$
220,292
70.3%
$
94,595
68.2%Share-based compensation expense
3783221,081947Levitronix fair market value inventory adjustments
1,386-1,386-Gross profit from continuing operations on a non-GAAP basis
$
73,450
71.6%
$
2,697
68.9%$
222,759
71.1%
$
95,542
68.5%The following table reconciles the specific items excluded from GAAP operating expenses from continuing operations in the calculation of non-GAAP operating expenses from continuing operations for the periods shown below: THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Operating Expenses from Continuing Operations(Unaudited)(in thou
'/>"/>
| SOURCE Thoratec Corporation Copyright©2010 PR Newswire. All rights reserved |